ATE524456T1 - Zur behandlung von erkrankungen, die auf eine modulation des serotonin-5-ht6-rezeptors ansprechen, geeignete chinolinverbindung - Google Patents

Zur behandlung von erkrankungen, die auf eine modulation des serotonin-5-ht6-rezeptors ansprechen, geeignete chinolinverbindung

Info

Publication number
ATE524456T1
ATE524456T1 AT08735447T AT08735447T ATE524456T1 AT E524456 T1 ATE524456 T1 AT E524456T1 AT 08735447 T AT08735447 T AT 08735447T AT 08735447 T AT08735447 T AT 08735447T AT E524456 T1 ATE524456 T1 AT E524456T1
Authority
AT
Austria
Prior art keywords
serotonin
receptor
modulation
treatment
compound suitable
Prior art date
Application number
AT08735447T
Other languages
English (en)
Inventor
Sean Colm Turner
Andreas Haupt
Wilfried Braje
Udo Lange
Karla Drescher
Karsten Wicke
Liliane Unger
Mario Mezler
Wolfgang Wernet
Matthias Mayrer
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Application granted granted Critical
Publication of ATE524456T1 publication Critical patent/ATE524456T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT08735447T 2007-03-23 2008-03-20 Zur behandlung von erkrankungen, die auf eine modulation des serotonin-5-ht6-rezeptors ansprechen, geeignete chinolinverbindung ATE524456T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07104806 2007-03-23
PCT/EP2008/053387 WO2008116831A1 (en) 2007-03-23 2008-03-20 Quinoline compounds suitable for treating didorders that respond to modulation of the serotonin 5-ht6 receptor

Publications (1)

Publication Number Publication Date
ATE524456T1 true ATE524456T1 (de) 2011-09-15

Family

ID=39620293

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08735447T ATE524456T1 (de) 2007-03-23 2008-03-20 Zur behandlung von erkrankungen, die auf eine modulation des serotonin-5-ht6-rezeptors ansprechen, geeignete chinolinverbindung

Country Status (24)

Country Link
US (1) US8242102B2 (de)
EP (1) EP2139880B1 (de)
JP (1) JP5538907B2 (de)
KR (1) KR20090128426A (de)
CN (1) CN101679351B (de)
AR (1) AR068381A1 (de)
AT (1) ATE524456T1 (de)
AU (1) AU2008231787A1 (de)
BR (1) BRPI0809081A2 (de)
CA (1) CA2681030C (de)
CO (1) CO6230989A2 (de)
CR (1) CR11039A (de)
DO (1) DOP2009000228A (de)
EC (1) ECSP099651A (de)
ES (1) ES2373617T3 (de)
IL (1) IL201105A0 (de)
MX (1) MX2009010243A (de)
NZ (1) NZ579735A (de)
PE (1) PE20091187A1 (de)
RU (1) RU2009139073A (de)
TW (1) TW200940524A (de)
UA (1) UA97837C2 (de)
UY (1) UY31326A (de)
WO (1) WO2008116831A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130343993A1 (en) * 2012-01-06 2013-12-26 Abbvie Inc. Radiolabeled 5-ht6 ligands
US20140120036A1 (en) * 2012-01-06 2014-05-01 Abbvie Inc. Radiolabeled 5-ht6 ligands
AR106515A1 (es) 2015-10-29 2018-01-24 Bayer Cropscience Ag Sililfenoxiheterociclos trisustituidos y análogos
WO2017157929A1 (en) * 2016-03-14 2017-09-21 AbbVie Deutschland GmbH & Co. KG Quinoline compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor
CN109053524A (zh) * 2018-09-11 2018-12-21 山东谛爱生物技术有限公司 一种N-Boc-3-羟基氮杂环丁烷的制备方法
CN109503449A (zh) * 2018-12-17 2019-03-22 天津药明康德新药开发有限公司 一种3-硝基吖丁啶-1-甲酸叔丁酯的合成方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001017991A1 (en) * 1999-09-02 2001-03-15 Wakunaga Pharmaceutical Co., Ltd. Quinolinecarboxylic acid derivative or its salt
JP2003277416A (ja) * 2002-03-22 2003-10-02 Daiyanitorikkusu Kk 糖類を含むアクリルアミド水溶液
US7452888B2 (en) * 2002-03-27 2008-11-18 Glaxo Group Limited Quinoline derivatives and their use as 5-ht6 ligands
US20050165006A1 (en) 2002-04-03 2005-07-28 Dae-Yoon Chi Quinoline derivatives, their preparation and pharmaceutical compositions comprising the same
MXPA04012122A (es) 2002-06-05 2005-04-19 Hoffmann La Roche Derivados de 1-sulfonil-4-aminoalcoxi indol como moduladores del receptor 5-hidroxitriptamina 6 (5-5-ht6) para tratamiento de trastornos del sistema nervioso central (snc).
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7227023B2 (en) 2003-04-30 2007-06-05 Wyeth Quinoline 3-amino chroman derivatives
GB0321473D0 (en) 2003-09-12 2003-10-15 Glaxo Group Ltd Novel compounds
GB0411421D0 (en) * 2004-05-21 2004-06-23 Glaxo Group Ltd Novel compounds
CN101228130A (zh) * 2005-07-27 2008-07-23 弗·哈夫曼-拉罗切有限公司 芳氧基喹啉和其作为5-ht6的用途
GB0519765D0 (en) * 2005-09-28 2005-11-09 Glaxo Group Ltd Novel compounds
US20100041672A1 (en) 2007-03-21 2010-02-18 Glaxo Group Limited Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome

Also Published As

Publication number Publication date
TW200940524A (en) 2009-10-01
BRPI0809081A2 (pt) 2019-09-24
CN101679351A (zh) 2010-03-24
RU2009139073A (ru) 2011-04-27
NZ579735A (en) 2012-02-24
IL201105A0 (en) 2010-05-17
ECSP099651A (es) 2009-10-30
UY31326A (es) 2009-11-10
CO6230989A2 (es) 2010-12-20
CR11039A (es) 2010-02-09
JP2010521520A (ja) 2010-06-24
AU2008231787A1 (en) 2008-10-02
CA2681030C (en) 2015-01-13
HK1139933A1 (en) 2010-09-30
ES2373617T3 (es) 2012-02-07
CN101679351B (zh) 2015-01-07
AR068381A1 (es) 2009-11-11
PE20091187A1 (es) 2009-09-06
CA2681030A1 (en) 2008-10-02
EP2139880A1 (de) 2010-01-06
DOP2009000228A (es) 2009-10-15
UA97837C2 (ru) 2012-03-26
JP5538907B2 (ja) 2014-07-02
US8242102B2 (en) 2012-08-14
US20110009380A1 (en) 2011-01-13
KR20090128426A (ko) 2009-12-15
WO2008116831A1 (en) 2008-10-02
MX2009010243A (es) 2009-12-14
EP2139880B1 (de) 2011-09-14

Similar Documents

Publication Publication Date Title
LTC2137143I2 (lt) Pleuromutilino dariniai, skirti mikrobų sukeltų ligų gydymui
LTPA2020510I1 (lt) Pakeistieji 4-fenil-piridinai, skirti su NK-receptoriumi susijusių ligų gydymui
BRPI0908026A2 (pt) Métodos para o tratamento de doenças do intestino
EP2470553C0 (de) Polyhydroylierte gallensäure zur behandlung von gallenerkrankungen
EP2111223A4 (de) Aminderivatverbindungen zur behandlung von augenerkrankungen und -leiden
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
EP2182983A4 (de) Behandlung von amyloidogenen erkrankungen
ATE534633T1 (de) Indazolderivate zur behandlung von hsp90- induzierten krankheiten
ATE434620T1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
EA201491933A1 (ru) Дигидрат соединения бензотиофена или его соли и способ его получения
EP2512240A4 (de) Verfahren und zusammensetzungen zur behandlung und prävention von trigeminoautonomen zephalgien, migräne und gefässerkrankungen
DE602006019838D1 (de) Piperazinsubstituierte benzothiophene zur behandlung von geisteskrankheiten
EP2135858A4 (de) Zusammensetzung zur behandlung von infektionserkrankungen
EP2278999C0 (de) Ohrbehandlungsformulierungen zur behandlung von ohrenerkrankungen und -leiden
EP3466408C0 (de) Flüssige pharmazeutische zusammensetzung zur behandlung von erkrankungen des hinteren auges
LT3135672T (lt) Kompozicijos ir būdai skirti gydyti alkoholio vartojimo sutrikimus, skausmą ir kitas ligas
BRPI0911577A2 (pt) derivados espiro-indol para o tratamento de doenças parasíticas.
EA201170356A1 (ru) Полиморфные и аморфные формы лакозамида и аморфные композиции
DE602008000403D1 (de) Behandlung von medizinischen Implantaten, die kalkbeständig sind
LT3045474T (lt) Terapiniai agentai, skirti gydyti ligas, susijusias su nepageidaujama ląstelių proliferacija
ATE532507T1 (de) Neramexane zur behandlung von subakuten tinnitus
ATE476414T1 (de) Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen
EP2718255A4 (de) Chinonverbindungen zur behandlung ape1-vermittelter krankheiten
ATE524456T1 (de) Zur behandlung von erkrankungen, die auf eine modulation des serotonin-5-ht6-rezeptors ansprechen, geeignete chinolinverbindung
EP2249765A4 (de) Dapson zur behandlung von rosascea

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties